Ono Pharmaceutical Co., Ltd. (OPHLF)

Overview

Ono Pharmaceutical Co., Ltd., established in 1717, operates globally from its headquarters in Osaka, Japan. The company, along with its subsidiaries, is engaged in the production, purchase, and distribution of pharmaceuticals and diagnostic reagents globally. Ono Pharmaceutical is conspicuous in the healthcare sector for its innovative contributions towards treatments for various ailments, including cancer, diabetes, heart failure, Alzheimer's disease, and more. Its business operations extend beyond product sales to encompass strategic collaborations with entities like Adimab, LLC, Turbine Ltd., Harvard University, and Sibylla Biotech for research and development in novel therapies. These collaborations underline Ono Pharmaceutical's commitment to advancing healthcare through innovation.

Products and Services

Opdivo Intravenous Infusion and Kyprolis Intravenous Injection: Treatments for malignant tumors, showcasing the company's focus on oncology.

Emend capsules/Proemend intravenous injections: Designed for the management of chemotherapy-induced nausea and vomiting, improving the quality of life for cancer patients undergoing chemotherapy.

Demser capsules: Aimed at treating symptoms in patients with pheochromocytoma, a rare tumor condition.

Mektovi, Velexbru, and Braftovi capsules: Targeted therapies for malignant tumors, displaying a variety of options in cancer treatment.

ADLUMIZ tablets: Employed in the management of cancer cachexia, helping patients maintain weight and muscle mass.

Glactiv tablets and Forxiga tablets: Offered for the treatment of type 2 diabetes, reflecting the company's effort in addressing this widespread condition.

Onoact Intravenous Infusion: A solution for tachyarrhythmia, demonstrating the company's presence in cardiovascular treatments.

Opalmon tablets: Intended for the treatment of peripheral circulatory disorder, enhancing blood flow to extremities.

Coralan: Used for chronic heart failure, indicating the company's commitment to cardiovascular health.

Orencia injections: Target rheumatoid arthritis, offering relief to patients with autoimmune diseases.

Rivastach patches: A treatment for Alzheimer's disease, showcasing efforts in neurodegenerative disorder management.

Ongentys tablets: Prescribed for Parkinson's disease, underlining the company's focus on neurological conditions.

Parsabiv intravenous infusion: Designed for dialysis patients, addressing complications from kidney failure.

Staybla tablets: For overactive bladder, contributing towards improving quality of life in urinary conditions.

Onon capsules and Dry Syrups: Aimed at treating bronchial asthma and allergic rhinitis, reflecting efforts in respiratory conditions.

JOYCLU intra-articular injection: For the improvement of joint function, catering to patients with joint-related disorders.

Recalbon tablets: Used in the treatment of osteoporosis, helping in the management of bone health.

In addition to these products, Ono Pharmaceutical is actively involved in the development of treatments for a wide array of diseases, including various types of cancer, acute myeloid leukemia, solid tumors, myelodysplastic syndrome, melanoma, T-cell lymphoma, and more, extending its research to conditions like pemphigus, scleroderma, seizures, diabetic polyneuropathy, neurodegenerative, autoimmune diseases, narcolepsy, and thrombosis. These endeavors in drug development underscore the company's comprehensive approach to healthcare and its relentless pursuit of groundbreaking treatments.